Kornimate/medical-research-clean huggingface dataset:
biphasic effects of acute alcohol intoxication on bystander intervention

Conditions: Alcohol Intoxication

Summary: the goal of this experimental study is to examine the effect of alcohol, gender, and bystander attitudes on bystander barriers and sexual violence intervention among young adult men and women (age 21-20). the main questions it aims to answer are: * does alcohol intoxication and gender influence bystander barriers and sexual violence intervention? * does alcohol intoxication have a greater impact on bystander barriers and sexual violence intervention among men, compared to women? * does alcohol intoxication have a greater impact on bystander barriers and sexual violence intervention among those with higher, compared to lower, prosocial bystander attitudes? participants will be randomly assigned to one of two beverage conditions (alcohol or control beverage) and those assigned to alcohol will complete the study on either the ascending or descending alcohol limb. participants will project themselves into a heat-of-the moment, risky sexual violence scenario that will assess bystander barriers and behavioral intentions. researchers will compare those assigned to the alcohol and control beverage condition and men/women to see if this impacts bystander barriers and sexual violence intervention.


Eligibility criteria:
inclusion criteria: * between the ages of 21 and 30 * report that on at least 3 days in the past year they have consumed an alcohol quantity on a single occasion that was equal or greater to the dose administered in the lab exclusion criteria: * currently seeking treatment or in recovery for an alcohol or substance use disorder * a medical condition or medication use in which alcohol consumption is medically contraindicated * pregnant, nursing, or has engaged in sexual intercourse without effective contraception in the past two weeks * if the participant is less than six feet tall and weighs over 250 pounds or is over six feet tall and weighs over 300 pounds
treating schizophrenia by correcting abnormal brain development

Conditions: Schizophrenia

Summary: the purpose of this study is to determine whether treatment with tiagabine (gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. this study is funded by the national institutes of health.

it is hypothesized that enhancement of gaba neurotransmission during the early course of the illness by tiagabine (gabitril), a gaba transporter gat-1-specific inhibitor and a fda-approved anticonvulsant, will improve both clinical symptoms and working memory in schizophrenia. this improvement is postulated to be the result of tiagabine-mediated modification of the developmental synaptic pruning of prefrontal cortical circuitry. the occurrence of circuitry modification after tiagabine treatment will be assessed by the following independent methodologic approaches: mri morphometric analysis of prefrontal gray matter volume and fmri measurements of brain activity patterns during performance of tasks that probe working memory.

Eligibility criteria:
inclusion criteria: * meets criteria for the diagnosis of schizophrenia, with onset of psychotic symptoms within the past 3 years. * currently on second-generation antipsychotics for at least 3 months. * age 18-25, otherwise healthy. exclusion criteria: * diagnosis of schizoaffective disorder. * has failed two or more clinically adequate antipsychotic trials. * history of seizures or any neurologic disorders. * pregnant or nursing women. * known hiv infection. * actively suicidal. * history of any substance dependence. * currently meets criteria for substance abuse/dependence. * other mri exclusion criteria per radiology department protocols.

Keywords: treatment fmri cognition brain development
safety study of non-invasive ventilation versus high-flow oxygen in patients with hypoxemic respiratory failure undergoing fiberoptic bronchoscopy.

Conditions: Respiratory Failure

Summary: bronchoscopy with broncho-alveolar lavage is a diagnostic tool in patients with pneumonia. especially patients with acute or chronic pulmonary diseases are at risk of respiratory failure during or after bronchoscopy. it is known that in these cases bronchoscopy can be performed safely using non-invasive ventilation. it seems probable that high-flow oxygen, which is used in the treatment of patients with hypoxemic respiratory failure, is equally effective in preventing the development of respiratory failure during fiberoptic bronchoscopy while improving patient comfort. in this prospective randomised study the safety of high-flow oxygen is compared with non-invasive ventilation in patients with hypoxemic respiratory failure undergoing fiberoptic bronchoscopy.


Eligibility criteria:
inclusion criteria: * patients treated in an intensive care unit * indication for bronchoscopy and broncho-alveolar lavage * presence of hypoxemic (sao2/fraction of inspired oxygen(fio2): 300 or less) and/or hypercapnic respiratory failure exclusion criteria: * patients already on invasive ventilation * indication for intubation * blocked nasopharynx * contraindications for non-invasive ventilation or high-flow oxygen
trunk and upper extremities program effect in decreasing compensation patterns in unilateral cerebral palsy children

Conditions: Cerebral Palsy Infantile; Chronic Pain; Upper Extremity Dysfunction

Summary: the goal of this clinical trial is to test the effectiveness of a trunk and upper extremities exercise program. the main questions it aims to answer are: whether the program decreases compensation patterns in unilateral cerebral palsy children whether the program decreases pain in unilateral cerebral palsy children whether the program improves bimanual ability in unilateral cerebral palsy children participants will undertake and 8-week program exercise at home if there is a comparison group: researchers will compare with the control group to see if this program decreases compensation patterns.

children in control group will continue with their daily activities. children in experimental group, apart from their daily activities, will undertake an 8-week program exercise at home for strengthening the trunk and the proximal part of both upper extremities. it contains 3 progressions that can be applied if needed.

Eligibility criteria:
inclusion criteria: * unilateral cerebral palsy diagnostic * level i or ii of the manual ability scale classification exclusion criteria: * have received any intervention with botulinum toxin or shock waves in the previous six months or have them scheduled during the intervention * are undergoing treatment with intensive therapies. * to have known alteration in the hips * have very serious attention or comprehension difficulties that prevent them from following instructions. * suffer uncontrolled epilepsies * suffer from severe visual problems.

Keywords: compensation patterns unilateral cerebral palsy
the influence of vertebral mobility on low back pain in patients with acute osteoporotic vertebral fractures

Conditions: Osteoporotic Vertebral Fracture

Summary: many patients with acute osteoporotic vertebral fracture (acute ovfs) admitted because of low back pain. but there are only part of patients with acute ovfs, because some patients do not have low back pain although ovfs occurred.

many patients of acute ovfs present with low back pain. while there are also many patients without low back pain even if acute ovfs occurred. the mechanism of low back pain after acute ovfs is well unknown. we set up a hypothesis that low back pain results from vertebral body mobility, which refers to a change of vertebral height or configuration with changes in body positioning. the main objective of this study is to reveal the relationship between vertebral body mobility and low back pain.

Eligibility criteria:
inclusion criteria: * patients with acute osteoporosis fractures exclusion criteria: * patients without acute osteoporosis fractures (metastasis, infection, deformity,etc)

Keywords: vertebral fracture, low back pain, gips, mobility
routine clinical screening for substance use disorders in the emergency room setting

Conditions: Substance Use

Summary: to ensure consistent documentation of alcohol and substance use, the emergency medicine is initiating a new standard of care for substance use screening: the use of a brief self-evaluation questionnaire on alcohol, tobacco and illicit substance use to be completed in triage. this questionnaire will allow emergency medicine patients presenting to the emergency room. this study will also review medical records after one year of the index emergency room visit to establish rates or re-presentation and hospitalization correlated with different substance use.

screening for alcohol use and substances of abuse in the emergency and trauma settings is critical for both effective current treatment of the presenting clinical issue and prevention of future incidents. identification, engagement and treatment of substance use disorders decreased trauma and emergency department visits and medical comorbidities (bertholet et al., 2005; kaner et al., 2007). to ensure consistent documentation of alcohol and substance use, the emergency medicine is initiating a new standard of care for substance use screening: the use of a brief self-evaluation questionnaire on alcohol, tobacco and illicit substance use to be completed in triage. this questionnaire will allow emergency medicine patients presenting to the emergency room. this research study will perform a chart review on all self-evaluation questionnaires on alcohol, tobacco and substance use to determine the prevalence of use of specific substances in this patient population and associated demographic predictors and medical comorbidities. this study will also review medical records after one year of the index emergency room visit to establish rates or re-presentation and hospitalization correlated with different substance use.

Eligibility criteria:
inclusion criteria: * able to complete a questionnaire exclusion criteria: * younger than 19 unable or unwilling to complete a self-assessment form written in english prisoners
advanced electronic population health and personal health record tools to improve once lifetime hepatitis c screening

Conditions: Hepatitis C

Summary: this study involves randomizing patients due for once in a lifetime hepatitis c screening based on center for disease control and prevention and united states preventative services task force guidelines in one of three primary care clinics within the metrohealth system to bulk messaging and bulk ordering for hcv antibody vs usual care (routine alerting).

all patients had to have an active personal health record account at the time of being randomized. patients had to have been seen by their primary care provider in the last 6 months to be eligible and therefore had a "missed opportunity" for hepatitis c screening. control group received "usual care" which in our system included alert (health maintenance reminder) to the primary care provider at the time of the visit and passive alert in their personal health record (i.e. an alert if they log into their personal health record and look for reminders for preventative care that it due/overdue). intervention group received same care as control group plus automatic ordering of the hepatitis c screening test and active electronic letter their personal health record that they were due for hepatitis c screening, what hepatitis c is, what the testing and if positive, treatment could involve, and instruction to go to one of the laboratories in the healthcare system to have their blood drawn if they were interested in the testing.

Eligibility criteria:
inclusion criteria: * seen recently in one of the three primary care study sites and have an active person health record at the time of randomization; and meet centers for disease control and prevention/united states preventative services task force guidelines for once in a lifetime hepatitis c screening exclusion criteria: * already had once in a lifetime screen for hepatitis c or positive for hepatitis c (by lab test or international classification of disease code)

Keywords: preventative screening electronic health records personal health records population health tools
investigating the use of prolia (denosumab) in the treatment of acute charcot neuroarthropathy

Conditions: Charcot Joint of Foot

Summary: charcot neuroarthropathy (cn) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. the consequences of cn include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. these consequences frequently lead to below-knee amputation of the affected limb. currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. the purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage charcot neuroarthropathy.


Eligibility criteria:
inclusion criteria: * men or women \> 30 years old * subject is able and willing to comply with study procedures, and is able to give signed and dated consent * subject meets criteria for diagnosis of diabetes mellitus type 1 or 2, active charcot neuroarthropathy, and peripheral neuropathy * subjects with serum calcium or albumin-adjusted serum calcium ≥2.0 mmol/l (8.0mg/dl) exclusion criteria: * unable to provide signed and dated consent. * charcot neuroarthropathy of the ipsilateral lower extremity, diagnosed over 1 month prior. * prior foot or ankle surgery of the ipsilateral lower extremity. * prior amputation at any level of either lower extremity. * prior foot or ankle fracture of the ipsilateral lower extremity unrelated to the current acute cn episode. * currently has any of the following: 1. infection 2. foot ulceration 3. hypocalcemia 4. creatinine clearance less than 30 ml/min or on dialysis 5. pre-existing disturbance of mineral metabolism (e.g., hypoparathyroidism unstable on therapy, thyroid or parathyroid surgery, vitamin d deficiency, malabsorption syndromes, excision of small intestine, history of diseases affecting bone metabolism) that has not been effectively corrected or treated. * have undergone revascularization procedures of the lower extremities. * female subjects who are pregnant or planning to breastfeed should not participate in this study. * determined to have poor oral hygiene after dental screening or are at increased risk for developing osteonecrosis of the jaw. * history of osteonecrosis of the jaw. * history of tooth extraction or other dental surgery within the prior 6 months. * invasive dental work planned in the next 2 years. * have a known hypersensitivity to prolia. * known use of a bone active medication within the 6 months prior to enrollment. * liver disease, defined as ast \> 2.0x uln, alt \> 2.0x uln, tbl \> 1.5x uln. * malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma)
clinical study for the efficacy and safety of ropeginterferon alfa-2b in moderate covid19.

Conditions: COVID-19

Summary: to evaluate the efficacy of subcutaneous ropeginterferon alfa 2b ( p1101combined with standard of care (soc) compared with standard care alone in hospitalized adults with moderate covid 19.


Eligibility criteria:
inclusion criteria: 1. ability to comprehend and willingness to provide a written icf before enter the study; 2. male or non-pregnant female patients, ≥ 20 years of age at the time of enrolment; 3. hospitalized patient with a diagnosis of covid-19 on the basis of a positive# reverse transcriptase polymerase chain reaction (rt-pcr) with moderate## disease on admission###. #: ct value \<30. ##:disease severity as defined by the treatment guidance of taiwan centers for disease control (cdc): \> moderate: pneumonia patients without severe symptoms, blood oxygen saturation ≥93% without supplemental oxygen equipment (on room air); ###: confirmed positive rt-pcr result ≤ 4 days prior to screening visit is eligible 4. agrees to the collection of pharyngeal swabs and blood sample as per protocol. exclusion criteria: 1. known history or presence of decompensated cirrhosis of the liver (child-pugh b or c) before study entry. 2. patients with intubation, respiratory failure, septic shock, multiple organ dysfunction or need additional organ support (e.g. vasopressors or ecmo). 3. patients who have spo2 \ 30 breaths/min. 4. patients treated by dexamethasone before day 1. 5. patients treated by supplemental oxygen (fio2 \>40%) before day 1. 6. stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. egfr \<15 ml/min/1.73 m2). 7. females who are breast-feeding, lactating, pregnant or intending to become pregnant. 8. known history of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of ropeginterferon alfa-2b. 9. known history or presence of poorly controlled or clinically significant medical conditions that are not suitable to be enrolled, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bipolar disorder, schizophrenia, suicidal ideation or history of suicidal attempt). 11. clinically significant medical conditions known to interfere with absorption, distribution, metabolism or excretion of the study drugs. 12. patients treated by monotherapy of telbivudine or any other combination therapy with telbivudine within 1 month prior to screening. 13.therapy with any anti-neoplastic, or immunomodulatory treatment within 1 month prior to screening. 14. patient who have been vaccinated with any live attenuated vaccine or covid- 19 vaccine within 1 month prior to screening. 15. use of an investigational medical product within 1 month prior to screening.
a study of cisapride in premature infants with feeding problems

Conditions: Infant, Premature; Infant, Newborn

Summary: the purpose of this study is to evaluate the effectiveness of cisapride in improving feeding problems in premature newborn infants.

this is a double-blind study where the identity of the treatment assigned (cisapride or placebo) will not be known to the patient's legal guardian or any study staff involved with the study. patients will be randomized (assigned by chance) to receive either the drug cisapride or a placebo (a placebo is identical in appearance to cisapride but does not contain cisapride or any active drug) to see if cisapride is effective in improving feeding problems (referred to as feeding intolerance) in premature newborn infants who cannot tolerate oral feeding by mouth or through a tube going directly to the stomach or intestine. patients will be given either cisapride at a dose of 0.2 mg/kg or placebo as a liquid suspension through a tube from the nose to the stomach (referred to as a nasogastric tube) 15 minutes before feeding once every 6 hours (or 4 times a day referred to as a q.i.d. schedule).

Eligibility criteria:
inclusion criteria: * must be hospitalized and on continuous cardiac monitoring for the duration of the study * patient has demonstrated feeding intolerance as defined by the protocol * patient's parent or legal guardian must sign the informed consent form exclusion criteria: * currently active significant cardiovascular disease, as determined by the neonatologist/physician, including congenital heart disease and heart block (patent ductus arteriosus without cardiac compromise at the time of randomization is acceptable)

Keywords: cisapride (prepulsid) feeding intolerance enteral feeding nasogastric tube neonate
a phase ii, multicentre, randomized, two-arm blinded study to assess the efficacy and safety of two lxe408 regimens for treatment of patients with primary visceral leishmaniasis

Conditions: Primary Visceral Leishmaniasis

Summary: this is a phase ii, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary vl.

this study is run by dndi with novartis as co-development partner

Eligibility criteria:
inclusion criteria: * male and female patients ≥ 18 years (at the time of the screening visit) who are able to comply with the study protocol. following a favourable interim analysis result, patients ≥12 \<18 years will also be enrolled in the trial * patients for whom written informed consent has been obtained (if aged 18 years and over) or signed by parent(s) or legal guardian for patients under 18 years of age. in the case of minors, assent from the child also needs to be obtained * primary symptomatic vl (defined as typical parameters including, but not limited to, fever for \> 2 weeks, weight loss, and splenomegaly) * visualization of leishmania amastigotes by microscopy in tissue samples (spleen or bone marrow) exclusion criteria: * clinical signs of severe vl (jaundice, spontaneous bleeding, edema, ascites, coma, organ failure) * laboratory abnormalities including alt/sgpt \> 3 times uln, total bilirubin \> 1.5 times uln, creatinine \>1.5 times uln, amylase or lipase \> 1.5 times uln, haemoglobin \< 6 g/dl or other clinically significant abnormal laboratory parameters which, in the opinion of the investigator, may indicate severe vl * patients with history of previous leishmaniasis and confirmed relapse * patients with para-kala-azar dermal leishmaniasis * patients with severe malnutrition (for children ≥12-\<18 years: bmi-for-age who reference curves by sex, z score \< -3; for adults ≥18 years: bmi \< 16) * history of congenital or acquired immunodeficiency, including positive hiv (test at screening) * known hypersensitivity to amphotericin b deoxycholate or any other constituents of ambisome® * concomitant infections such as tuberculosis, severe malaria, or any other serious underlying disease that may interfere with the disease assessment (e.g., cardiac, renal, hepatic, haematologic, and pancreatic) * infection with hepatitis b (hbv) or hepatitis c virus (hcv). a positive hbv surface antigen (hbsag) test, or if standard local practice, a positive hbv core antigen test, excludes a subject. patients with a positive hcv antibody test should have hcv rna levels measured. patients with positive (detectable) hcv rna should be excluded. * pregnant or nursing (lactating) women * women of childbearing potential who do not accept to have a pregnancy test done at screening and/or who do not agree to use highly effective contraception while taking the investigational drug and for 5 half-lives or 5 days, whichever is longer, after stopping the investigational drug. * sexually active males unwilling to use a condom during intercourse while taking the investigational drug and for 5 half-lives or 5 days, whichever is longer, after stopping the investigational drug.
study assessing double-masked uveitis treatment

Conditions: Uveitis; Posterior, Disorder

Summary: the purpose of this study is to evaluate the safety and efficacy of intravitreal injections of de-109 ophthalmic solution.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of active uveitis * 18 years of age or older * sign informed consent * meet best corrected etdrs visual acuity exclusion criteria: * uveitis of infectious etiology * suspected/confirmed central nervous system or ocular lymphoma * primary diagnosis of anterior uveitis * uncontrolled glaucoma * use of topical oculary medication * implanted device * significant ocular disease * lens/media opacities or obscured ocular media * intraocular surgery or treatments * capsulotomy * ocular or periocular infection * pupillary dilation * history of herpetic infection * toxoplasmosis or toxoplasmosis scar * ocular malignancy * allergy or hypersensitivity to study drug * participation in other uveitis trial within 30 days * monoclonal antibody treatment or biologic therapy * any systemic condition/infection * immunosuppressive therapy or immunocompromised * malignancy remission * females who are pregnant or lactating and females not using adequate contraceptives